Texas A&M Develops Groundbreaking Cancer Treatment Using Programmable Bacteria

A multi-university team, backed by federal funding, is pioneering a cost-effective bacterial therapeutic for precise cancer targeting at a single $1 dose. Traditional cancer treatments often entail harmful side effects, low patient responsiveness, and exorbitant costs. With a $20 million grant from the Advanced Research Projects Agency for Health (ARPA-H), led by Texas A&M University and the University of Missouri, this four-year initiative aligns with the Cancer Moonshot initiative, aiming to enhance cancer research and health outcomes.